Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 8, 2003, Pages 2513-2517

  Murray, Henry W ^a,c   Brooks, Elaine B ^a   DeVecchio, Jennifer L ^b   Heinzel, Frederick P ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Box 136 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CD40 LIGAND MONOCLONAL ANTIBODY; FGK 45; GAMMA INTERFERON; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 4 ANTIBODY; RECOMBINANT INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNOTHERAPY; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ADJUVANTS, IMMUNOLOGIC; AMPHOTERICIN B; ANIMALS; ANTIGENS, CD40; ANTIPROTOZOAL AGENTS; CRICETINAE; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED BALB C; TH2 CELLS;

EID: 0042268077     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.8.2513-2517.2003     Document Type: Article

References (41)

1. Balkhy, H. H., and F. P. Heinzel. 1999. Endotoxin fails to induce interferon-γ in endotoxin tolerant mice: deficiencies in both IL-12 heterodimer production and IL-12 responsiveness. J. Immunol. 162:3633-3638.
2. Bennett, J. E. 2001. Amphotericin B, p. 1295-1299. In J. C. Hardman and L. E. Limbird (ed.), Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. McGraw-Hill, New York, N.Y.
3. Berman, J. D., and D. J. Wyler. 1980. An in vitro model for chemotherapeutic agents in leishmaniasis. J. Infect. Dis. 142:83-86.
4. Bistoni, F., A. Vecchiarelli, R. Mazzolla, P. Puccetti, P. Marconi, and E. Geraci. 1985. Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob. Agents Chemother. 27:625-631.
5. Blanke, T. J., J. R. Little, S. F. Shirley, and R. G. Lynch. 1977. Augmentation of murine immune responses by amphotericin B. Cell. Immunol. 33:180-190.
6. Cenci, E., A. Mencacci, G. Del Sero, F. Bistoni, and L. Romani. 1997. Induction of protective Th1 responses to Candida albicans by antifungal therapy alone of in combination with an interleukin-4 antagonist. J. Infect. Dis. 176:217-226.
7. Cotterell, S. E., C. Engwerda, and P. M. Kaye. 1999. Leishmania donovani infection initiates T cell-independent chemokine responses which are subsequently amplified in a T cell-dependent manner. Eur. J. Immunol. 29:203-214.
8. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, and P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28:669-680.
9. Ferlin, W. G., T. von der Weid, F. Cottrez, D. A. Ferrick, R. L. Coffman, and M. C. Howard. 1998. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 MAb. Eur. J. Immunol. 28:525-531.
10. Groux, H., F. Cottrez, M. Rouleau, S. Mauze, S. Aantonenko, S. Hurst, T. McNeil, M. Bigler, M.-G. Roncarolo, and R. L. Coffman. 1999. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J. Immunol. 62:1723-1729.
11. Lehmann, J., K. H. Enssle, I. Lehmann, A. Emmendorfer, and M. L. Lohmann-Matthes. 2000. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice J. Interferon Cytokine Res. 20:63-77.
12. Louie, A., A. L. Baltch, and R. P. Smith. 1995. Fluconazole and amphotericin B antifungal therapies do not negate the protective effect of endogenous tumor necrosis factor in a murine model of fatal disseminated candidiasis. J. Infect. Dis. 171:406-415.
13. Martin, D. L., C. L. King, E. Pearlman, E. Strine, and F. P. Heinzel. 2000. IFN-γ is necessary but not sufficient for anti-CD40 antibody-mediated inhibition of the Th2 response to Schistosoma mansoni eggs. J. Immunol. 64:779-785.
14. Melby, P. C., Y.-Z. Yang, J. Cheng, and W. Zhao. 1998. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66:18-27.
15. Melby, P. C., A. Tabares, B. I. Restrepo, A. E. Cardona, H. S. McGuff, and J. M. Teale. 2001. Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection. Exp. Parasitol. 99:17-25.
16. Mencacci, A., E. Cenci, A. Bacci, F. Bistroni, and L. Romani. 2000. Host immune response determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis. J. Infect. Dis. 181:686-694.
17. Miralles, G. D., M. Y. Stoeckle, D. F. McDermott, F. D. Finkelman, and H. W. Murray. 1994. Induction of Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62:1058-1063.
18. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765.
19. Mozaffarian, N., J. W. Berman, and A. Casadevall. 1997. Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob. Agents Chemother. 41:1825-1829.
20. Murray, H. W., J. D. Berman, and S. D. Wright. 1988. Immunochemotherapy for intracellular Leishmania donovani infection: interferon-gamma plus pentavalent antimony. J. Infect. Dis. 157:973-978.
21. Murray, H. W., M. J. Oca, A., M. Granger, and R. D. Schreiber. 1989. Successful response to chemotherapy in experimental visceral leishmaniasis: requirement for T cells and effect of lymphokines. J. Clin. Investig. 83:1254-1259.
22. Murray, H. W., J. Hariprashad, and R. Fichtl. 1993. Treatment of experimental visceral leishmaniasis in a T cell-deficient host: response to amphotericin B and pentamidine. Antimicrob. Agents Chemother. 37:1504-1505.
23. Murray, H. W., and J. Hariprashad. 1995. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J. Exp. Med. 181:387-391.
24. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally-induced Th2 cell-associated response model. J. Exp. Med. 185:867-874.
25. Murray, H. W., C. Montelibano, R. Peterson, and J. P. Sypek. 2000. Interleukin 12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 182:1497-1502.
26. Murray, H. W., and S. Delph-Etienne. 2000. Role of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68:288-293.
27. Murray, H. W. 2001. Clinical and experimental advances in treatment in visceral leishmaniasis. Antimicrob. Agents Chemother. 45:2185-2197.
28. Murray, H. W. 2001. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int. J. Exp. Pathol. 82:249-276.
29. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kaplan, and R. L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70:6284-6293.
30. Murray, H. W., A. L. Moreira, C. M. Lu, J. L. DeVecchio, M. Matsuhashi, X. Ma, and F. P. Heinzel. Determinants of response to interleukin 10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J. Infect. Dis., in press.
31. Murphy, M. L., U. Wille, E. N. Villegas, C. A. Hunter, and J. P. Farrell. 2001. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 31:2848-2856.
32. Nabors, G. S. 1997. Modulating ongoing Th2-cell responses in experimental leishmaniasis. Parasitol. Today 13:76-79.
33. Rogers, P. D., J. K. Jenkins, S. W. Chapman, K. Ndebele, B. A. Chapman, and J. D. Cleary. 1998. Amphotericin B activation for human genes encoding for cytokines. J. Infect. Dis. 178:1726-1733.
34. Satoskar, A., H. Bluethmann, and J. Alexander. 1995. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63:4894-4899.
35. Satoskar, A. R., S. Rodig, S. R. Telford, A. A. Satoskar, S. K. Ghosh, F. von Lichtenberg, and J. R. David. 2000. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic pathology. Eur. J. Immunol. 30:834-839.
36. Spellberg, B., and J. E. Edwards. 2001. Type 1/type 2 immunity in infectious diseases. Clin. Infect. Dis. 32:76-102.
37. Stevens, D. A. 1998. Combination immunotherapy and antifungal chemotherapy. Clin. Infect. Dis. 26:1266-1269.
38. Stout, R. D., and J. Suttles. 1996. The many roles of CD40 in cell-mediated inflammatory responses. Immunol. Today 17:487-492.
39. Tokuda, Y., M. Tsuji, M. Yamazaki, S. Kimura, S. Abe, and H. Yamaguchi. 1993. Augmentation of murine tumor necrosis factor production by amphotericin B in vitro and in vivo. Antimicrob. Agents Chemother. 37:2228-2230.
40. Vonk, A. G., M. G. Netea, N. E. Denecker, I. C. Verschueren, J. W. van der Meer, and B. J. Kullberg. 1998. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J. Antimicrob. Chemother. 42:469-474.
41. Wolf, J. E., and S. E. Massof. 1990. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect. Immun. 58:1296-1300.